Top Markets
Coin of the day
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Rangering i aksjer #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Aksjekurs
$8.16
Sist synkronisert: 2025-06-26
Markedsverdi
$234.57M
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Regulus Therapeutics Inc. (RGLS)

Kategori

Antall utestående aksjer for Regulus Therapeutics Inc. (RGLS)
Antall utestående aksjer per March 2025: 66.17M
Ifølge Regulus Therapeutics Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 66.17M. Ved slutten av December 2023 hadde selskapet 18.96M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Regulus Therapeutics Inc. (RGLS) fra 2010 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
2026 (TTM) 66.17M 17.44%
2024 56.35M 197.18%
2023 18.96M 24.25%
2022 15.26M 78.05%
2021 8.57M 145.03%
2020 3.50M 102.65%
2019 1.73M 97.97%
2018 871.86K 0.61%
2017 866.58K 96.90%
2016 440.11K 2.73%
2015 428.43K 16.61%
2014 367.42K 14.58%
2013 320.66K 368.55%
2012 68.44K 3,099.49%
2011 2.14K 0.00%
2010 2.14K 0.00%
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
253.90M 283.68%
US
62.19M -6.03%
NL
396.00M 498.42%
US
478.91M 623.71%
AU
- -
CH